Lista de obras - Richard Slayden - Dominio Público Uruguay

A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927

scientific journal article

A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus

artículo científico publicado en 2010

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis

artículo científico publicado en 2014

Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis

artículo científico publicado en 2015

Analysis of the Lipids of Mycobacterium tuberculosis

artículo científico publicado el 1 de enero de 2001

Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection

artículo científico publicado en 2016

Benzimidazole-based antibacterial agents against Francisella tularensis

artículo científico publicado en 2013

Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model

artículo científico publicado en 2015

Cell wall structure of a mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids.

artículo científico publicado en 2000

Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery

artículo científico publicado en 2008

CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway.

artículo científico publicado en 2011

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

artículo científico publicado en 2003

Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.

artículo científico publicado en 2014

Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis

artículo científico publicado en 2007

Discovery of anti-TB agents that target the cell-division protein FtsZ.

artículo científico publicado en 2010

Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity

artículo científico publicado en 2009

Disease State Differentiation and Identification of Tuberculosis Biomarkers via Native Antigen Array Profiling

scientific article published on 09 August 2006

Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors

artículo científico publicado en 2017

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis

artículo científico publicado en 2016

FtsZ: a novel target for tuberculosis drug discovery

artículo científico publicado en 2007

Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis

artículo científico publicado en 2010

Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins

scientific journal article

Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis

scientific article published on 01 June 2006

Identification of the apparent carrier in mycolic acid synthesis

artículo científico publicado en 1994

Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei

artículo científico publicado en 2016

Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease.

artículo científico publicado en 2008

Implications of high level pseudogene transcription in Mycobacterium leprae

artículo científico publicado en 2009

In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis

artículo científico publicado en 2014

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

artículo científico publicado en 1998

Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.

artículo científico publicado en 2000

Isothermal amplification and molecular typing of the obligate intracellular pathogen Mycobacterium leprae isolated from tissues of unknown origins

artículo científico publicado en 2006

Iterative feature removal yields highly discriminative pathways

artículo científico publicado en 2013

MadR1, a Mycobacterium tuberculosis cell cycle stress response protein that is a member of a widely conserved protein class of prokaryotic, eukaryotic and archeal origin

artículo científico publicado en 2015

MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein

artículo científico publicado en 2013

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

artículo científico publicado en 2011

Mechanisms of isoniazid resistance in Mycobacterium tuberculosis

artículo científico publicado en 1998

Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence

artículo científico publicado en 2009

Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis

scientific journal article

Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response

artículo científico publicado en 2011

Mycolic acids: structure, biosynthesis and physiological functions

artículo científico publicado en 1998

Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents

artículo científico publicado en 2010

Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor

artículo científico publicado en 2014

SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents

artículo científico publicado en 2013

Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity

artículo científico publicado en 2009

Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia

artículo científico publicado en 2009

Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei

artículo científico publicado en 2013

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis

scientific journal article

Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis

artículo científico publicado en 2016

Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors

artículo científico publicado en 2008

Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents

artículo científico publicado en 2006

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors

artículo científico publicado en 2007

The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy

artículo científico publicado en 2013

The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection

artículo científico publicado en 2012

The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

artículo científico publicado en 2000

The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection

artículo científico publicado en 2013

The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis

scientific journal article

Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity

artículo científico publicado en 2016

Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy

artículo científico publicado en 2014

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response

artículo científico publicado en 2017

Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis

artículo científico publicado en 2003

Updating and curating metabolic pathways of TB.

artículo científico

Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs

artículo científico publicado en 2000

Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles

artículo científico publicado en 2006

Lista de obras de Richard Slayden

A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927

A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis

Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis

Analysis of the Lipids of Mycobacterium tuberculosis

Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection

Benzimidazole-based antibacterial agents against Francisella tularensis

Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model

Cell wall structure of a mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids.

Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery

CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway.

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.

Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis

Discovery of anti-TB agents that target the cell-division protein FtsZ.

Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity

Disease State Differentiation and Identification of Tuberculosis Biomarkers via Native Antigen Array Profiling

Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis

FtsZ: a novel target for tuberculosis drug discovery

Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis

Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins

Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis

Identification of the apparent carrier in mycolic acid synthesis

Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei

Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease.

Implications of high level pseudogene transcription in Mycobacterium leprae

In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.

Isothermal amplification and molecular typing of the obligate intracellular pathogen Mycobacterium leprae isolated from tissues of unknown origins

Iterative feature removal yields highly discriminative pathways

MadR1, a Mycobacterium tuberculosis cell cycle stress response protein that is a member of a widely conserved protein class of prokaryotic, eukaryotic and archeal origin

MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

Mechanisms of isoniazid resistance in Mycobacterium tuberculosis

Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence

Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis

Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response

Mycolic acids: structure, biosynthesis and physiological functions

Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents

Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor

SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents

Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity

Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia

Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis

Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis

Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors

Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors

The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy

The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection

The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection

The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis

Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity

Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response

Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis

Updating and curating metabolic pathways of TB.

Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs

Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles